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Abstract
Background: The 'False Consensus Effect' (FCE), by which people perceive their own actions as relatively
common behaviour, might be exploited to gauge whether a person engages in controversial behaviour,
such as performance enhancing drug (PED) use.
Hypothesis: It is assumed that people's own behaviour, owing to the FCE, affects their estimation of the
prevalence of that behaviour. It is further hypothesised that a person's estimate of PED population use is
a reliable indicator of the doping behaviour of that person, in lieu of self-reports.
Testing the hypothesis: Over- or underestimation is calculated from investigating known groups (i.e.
users vs. non-users), using a short questionnaire, and a known prevalence rate from official reports or
sample evidence. It is proposed that sample evidence from self-reported behaviour should be verified using
objective biochemical analyses.
In order to find proofs of concept for the existence of false consensus, a pilot study was conducted. Data
were collected among competitive UK student-athletes (n = 124) using a web-based anonymous
questionnaire. User (n = 9) vs. non-user (n = 76) groups were established using self-reported information
on doping use and intention to use PEDs in hypothetical situations. Observed differences in the mean
estimation of doping made by the user group exceeded the estimation made by the non-user group
(35.11% vs. 15.34% for general doping and 34.25% vs. 26.30% in hypothetical situations, respectively), thus
providing preliminary evidence in support of the FCE concept in relation to doping.
Implications of the hypothesis: The presence of the FCE in estimating doping prevalence or behaviour
in others suggests that the FCE based approach may be an avenue for developing an indirect self-report
mechanism for PED use behaviour. The method may be successfully adapted to the estimation of
prevalence of behaviours where direct self-reports are assumed to be distorted by socially desirable
responding. Thus this method can enhance available information on socially undesirable, health
compromising behaviour (i.e. PED use) for policy makers and healthcare professionals. The importance of
the method lies in its usefulness in epidemiological studies, not in individual assessments.
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The development of an epidemiology of performance
enhancing drug (PED) use in sport has been restricted by
the absence of a reliable and valid indicator of drug use
[1,2]. Where conventional drug testing indicates preva-
lence around 2% [3], estimates from "how many people
do you know who use PED" indicate the prevalence to be
6% [4] and in anecdotal reports up to 95% [5]. The
absence of a reliable indicator has significant implications
for assessing the value of interventions to ameliorate or
eliminate drug use in sport. There is, however, the poten-
tial to develop a self-report measure using a known bias in
human perceptions of social behaviour, the False Consen-
sus Effect (FCE).
As noted above, prevalence estimates for PED use in sport
range from 2% to 95%. Such a wide range of estimates
indicates that there is poor evidence about the actual prev-
alence rate. That is, there is no reliable epidemiology of
PED use among athlete populations [1]. Laure [6] reports
an attempt to develop an epidemiology of androgenic-
anabolic steroid (AAS) use in France, suggesting that 10–
20% of athletes use such substances regardless of age, sex
or sport. A comprehensive study across six European
countries that relied upon self reports among university
students indicated that 2.6% were willing to admit use of
PED [7].
The failure to generate an acceptable epidemiology is
predicated based upon the methods used to detect the
prevalence of PED use in sport being flawed. The admin-
istrative, financial and scientific constraints of biomedical
testing have become received wisdom with acknowledge-
ment of the drugs in sport 'arms race' between new drugs
and detection technologies. That is, biomedical detection
is unlikely to give an accurate indication of prevalence due
to the combination of an inability to test universally and
the introduction of drugs undetectable by contemporary
methods [8].
The application of typical social science methods to gen-
erating estimates of prevalence leads to problems such as
the reliability of self report, non-response bias or social
desirability [2]. Who is asking the question may also con-
taminate the response; it would be a brave athlete who
admitted to PED use on a survey run or sponsored by a
National Anti-Doping Organisation. Likewise, it would be
scientifically invalid to infer anything about substance use
behaviour from stated attitudes or intentions towards
PED use given the tenuous relationship between the two.
With the failure of typical biomedical or social science
approaches to provide a basis for developing an epidemi-
ology of PED use in sport, atypical approaches are called
for. One such atypical technique called the 'Random
Response Technique' (RRT) has proven to be more relia-
ble when sensitive issues such as abortion, illicit drug use,
opinion about capital punishment or shoplifting are
investigated [9-11]. Using the RRT, Simon and colleagues
recently showed a comparatively high (12.5%) prevalence
of doping use among gym users [12].
The aim of this paper is to propose an alternative indirect
approach which has been used in sociology but is new to
doping research and relies on social projection. The
notion of social projection was introduced more than 80
years ago [13] and the method has been extensively used
in social psychology [14-19]. The false consensus effect
arose from psychology's efforts to explain discrepancies in
social judgement. Specifically, the effect describes the con-
siderable overestimation of behaviour in which a person
engages, and a slight underestimation of behaviour absent
from a person's repertoire [18]. That is, over-estimating a
particular behaviour indicates that the person who makes
the estimate (and overestimates the behaviour) is likely to
be engaged in the same act. Research regarding attributive
projection (the tendency of people to project their own
characteristics onto others) [20], the FCE and uniqueness
bias have been particularly pervasive in social psychology
[18]. According to the FCE theory [21], individuals often
tend to overestimate the extent to which others behave the
same way as they do, especially if the behaviour in ques-
tion is deemed to be socially questionable or unaccepta-
ble. This phenomenon is explained by a part
motivational, part cognitive process resulting in people
believing that their own action is a relatively common
behaviour. The effect appears to be present even when
objective statistics and information on the bias effect are
provided, indicating the intractable and egocentric nature
of this biased social perception [22].
For example, self reporting marijuana smokers overesti-
mated the proportion of users in the general population
by 28% whereas non-smokers of marijuana overestimated
the rate of use by 14% [18]. The directions of these estima-
tions were congruent with the self-reported behaviours
(i.e. non-users under-estimated and users over-estimated)
in a study regarding students' use of amphetamines. In
this report students who abstained from amphetamines
typically underestimated (estimate 29% versus 35%
reported) and users overestimated (estimate 48%) preva-
lence of amphetamine use but not other behaviour, sug-
gesting that this FCE is behaviour-specific and does not
generalise to other similarly ostracised acts [19].
Recent marketing research investigating consumer behav-
iour demonstrated that overestimation is greater when an
individual holds positive feelings toward the subject [23].
In addition to finding further evidence for the FCE, Monin
& Norton [17] also demonstrated the existence of a strat-Page 2 of 8
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strategy typically involves justification based on the sense
of comfort in large numbers (i.e. many are doing so) or
citing special mitigating circumstances. It was also shown
that bias estimation (whether over or under-estimation) is
rooted in the social perception of the behaviour, not in
the behaviour itself [17]. The estimation of others' behav-
iour was influenced by the combination of two condi-
tions: i) the person's own behaviour and, ii) what was
desirable in the given situation. As such, estimation bias
may change over time as one or both of these conditions
change.
Whilst its causality has remained unknown, the relation-
ship between self-involvement and overestimation has
been repeatedly evidenced with regard to smoking, drink-
ing and illicit drug use [24-26]. It has been suggested that
perceived prevalence may act as a normatively prescribed
behaviour [24] and actually initiates the behaviour. For
example, if emerging athletes believed that using PEDs is
necessary to be successful in high performance sport and
that everyone uses PEDs, this belief may work as a per-
ceived norm for these athletes and motivates them to do
as the others and start taking PEDs. While it is a plausible
application of the FCE, its validity requires further evi-
dence, preferably from longitudinal studies. For the pur-
pose of the present proposal, it is sufficient to assume that
significant overestimation signals involvement, namely
doping use or intention to use.
Estimation of prevalence has also appeared in doping
research. Pearson & Hansen's study of athletes at the 1992
Winter Olympics provides an insight into how the FCE
might work in an anti-doping context [27]. In this study,
athletes were asked to estimate the prevalence of doping
or certain PEDs among their peers. For example, where the
reported positive cases vary around 2% [3], 67 of 155 ath-
letes (43%) surveyed by Pearson & Hansen thought that
more than 10% of athletes in their sports used anabolic
steroids, and a further 53 (34%) gave an estimate between
1% and 9% [27]. A survey conducted among Finnish
Olympic athletes revealed similar results. Whilst none
admitted using PEDs, 42.5% from stress power sports and
37.0% of endurance athletes reported that they personally
know another athlete who uses PEDs [28].
In the context of a review for WADA, Backhouse and col-
leagues report that unvalidated self-reported PED use
among elite athletes typically ranges between 1.2% and
8% [29]. Conversely, projective techniques where athletes
are asked to estimate how many team mates or competi-
tors used PED, the estimate increased to between 6% and
34%. This divergence in estimates appears large for ran-
dom sampling differences and may be better explained by
the FCE. Using FCE-based surveys may equip researchers,
policy makers and health care professionals with a more
realistic estimate of PED use by the athlete population. It
is envisaged that in its broader aspects, this study would
help to provide guidance for the general population with
respect to PED use, particularly for non-prescription ana-
bolic steroids, amphetamines and/or analgesics.
The hypothesis
Applying the FCE concept to PEDs in a sport context, it is
hypothesised that athletes who use PEDs overestimate
prevalence of doping in their sport and in sport more
broadly, compared to non-users. The measurement tool
we propose to develop for doping prevalence estimation
is based on the FCE, assuming that the effect is present for
illicit or banned drug use. What differentiates the pro-
posed approach from reported projected use is how the
estimation made by respondents is used. Typically esti-
mates are reported at face value and discussed as preva-
lence in the population. We propose to use estimates to
gain information about the individual who makes the esti-
mates and not the population for which the estimates are
made. While there are no epidemiology data for drugs in
sport against which to compare athlete responses [1], it is
the magnitude of over- or underestimation that may pro-
vide the indicator. The indirect nature of asking athletes
about prevalence may yield an indicator suitable for epi-
demiological and social science based research to begin
cross-sectional descriptive or prospective causal models of
athlete PED use.
Testing the hypothesis
Determining the level of over- or underestimation will be
conducted by calculating deviation from the publicly
established prevalence rate of 2% [3] and the prevalence
rate calculated from the presence of doping in the sample
(users/non-users). Estimates can be solicited in various
forms ranging from direct questions (i.e. 'In your opinion,
what percentage of others in your sport use PEDs?' or 'To
your knowledge, what proportion (%) of your fellow ath-
letes use PEDs?') to hypothetical scenarios (i.e. 'Under cir-
cumstances X, what percentage of the athletes would use
PEDs?'), where depending on the research question, using
different hypothetical situations can be used as experi-
mental manipulation. Estimates made by user and non-
user groups will be compared and the differences tested
for statistical significance:
H1: μ1 > μ2,
H2: (μ1 - P) > (μ2 - P)
where μ1 and μ2 denote population estimate for users and
non-users, respectively and P is the doping prevalence in
the population.Page 3 of 8
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provide empirical evidence for the FCE. Part of this test for
association includes developing an estimate for confi-
dence in the level of overestimation and their correspond-
ing odds ratios (OR). OR is defined as the ratio of the odds
of doping use occurring in one group (high prevalence
estimators) to the odds of it occurring in another group
(lower prevalence estimators), or to a sample-based esti-
mate of that ratio. The calculation of the odds ratio will be
based on Fisher's Exact Test (FET). The advantage of the
FET over a simple calculation of the odds ratio is that FET
provides a confidence interval for the odds ratio.
An OR of 1 indicates that doping use is equally likely in
both high- and low estimating groups. An OR greater than
1 indicates that doping is more likely (may be many
times) in the high estimators group, whereas an OR below
1 indicates that doping is less likely in this group in com-
parison to the other, low estimators group. Owing to the
phenomenon that OR sometimes overstates relative posi-
tions, it is proposed that the log OR value will be used.
Proposed approach to testing the hypothesis
Social psychology research on the FCE typically uses self-
reported data to create the two fundamental groups: those
who are involved in the investigated behaviour and those
who are not involved. In these cases, self reports on
behaviour were taken at face value and treated as a truth-
ful and accurate report on one's behaviour. Assuming that
such self reports, especially in regards to controversial
behaviour, are free of response bias is naïve and self-
reported information (when possible) should be verified
with or replaced by objective measures at least during the
pilot study phase. For example, such objective informa-
tion can be obtained via biochemical analyses. Hair anal-
yses, in particular, provide a non-invasive approach to the
simultaneous assessment of multiple metal ions used in
mineral supplements, steroids [30] and many social drugs
(cannabis, amphetamines, opiates and cocaine) that are
prohibited during competition. Hair analysis also has the
advantage of having a considerably longer detection win-
dow that allows testing for habitual use (chronic and past
consumption) of drugs [31]. Therefore, it is proposed that
self-reports will be corroborated with biochemical analy-
sis. More precisely, hair assays will be used to detect the
use of steroids, selected social drugs and multivitamins/
iron supplements as control measures. The biochemical
validation is then used to verify whether over- or underes-
timation is associated with use or abstinence and odd
ratios will be calculated based on the magnitude of over-
estimation by the user groups.
In cases when biochemical analyses for the entire sample
is not feasible (i.e. owing to large sample sizes in epidemi-
ological studies), it is suggested that biochemical analysis
should be used on a small representative sample prior to or
as part of the main data collection. This would provide
guidance as to what degree self-reports are distorted (most
likely under-reported) and information to be used to
adjust self-reports from large scale studies accordingly.
In recent years, rigorous methodologies have been devel-
oped and validated for the assessment of exposure to a
wide range of supplements, drugs and toxins, including
metal ions [32-35]. Hair samples should be untreated hair
cuts from close to the scalp, typically at the posterior ver-
tex, although pubic, axillary, arm, chest or thigh hair can
also be used with adjusted cut off values [31]. The samples
should be stored in paper envelopes or folded scaled
paper with ends fixed and marked if timescale was an
issue. Scalp hair normally grows approximately 100 mm
in every 30 days, therefore time or frequency of the drug
consumption can also be detected within the generally
accepted 90 days detection window.
For drug analyses, the hair samples are sectioned (>1 mm)
and stirred in methanol for 167 hours at 40°C prior to
evaporation [31]. Samples for metal ion analyses are sol-
ubilised by heating at 150°C for 30 min after adding a 2:1
HNO3: H2O2 mixture [33]. Methods have been developed
for analysis of metals, social and performance enhancing
drugs using inductively-coupled mass spectrometry (ICP-
MS), gas chromatography-tandem mass spectrometry
(GC-MS/MS) and liquid chromatography-tandem mass
spectrometry (LC-MS/MS).
Proof of concept: a pilot study
To establish the presence of the FCE in relation to doping,
a small scale pilot study was conducted. The primary aim
of this pilot study was to provide proof that the FCE is
present in the perception of doping behaviour. In addi-
tion, the study also served as validation of the measure-
ment tool (questionnaire) designed to obtain self-
reported information from the athletes.
Methods
To investigate whether a relationship exists between dop-
ing use and potential doping use and estimation of others'
use and potential use, a questionnaire was developed con-
taining questions of the following: i) self-reported doping
use (recorded as Y/N), ii) estimated doping use of others
(as %) and eight hypothetical scenarios of doping use
forming the Hypothetical Doping Scenarios (HDS). For
estimating potential doping behaviour of others, respond-
ents were asked to estimate the proportion (as %) of oth-
ers who would use doping. Respondents were also asked
to report whether or not they would use doping in a pre-
scribed situation (HDS-Self, recorded as Y/N). For the
questions, see Additional File 1: Direct doping estimate of
others, self reported doping behaviour, HDS and HDS-Page 4 of 8
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brief definition of the drugs (see Additional file 2: Defini-
tion of nutritional supplements and doping. In congru-
ence with the WADA regulation, there was no distintction
made between social drugs and other substances if they
were used for performance anhenacing purposes.
Analyses
Self reports were used to establish the user categories. The
HDS-Self score was used to group participants as users vs.
non-users, where athletes with HDS-Self ≥ 1 were classi-
fied as potential user. Direct self report had binary values
(No = 0, Yes = 1). For the purpose of the analyses, only
those athletes were considered doping users who were
classified 'user' in both categories (direct report and hypo-
thetical use). Similarly, non-user athletes were those who
were classified as 'non-users' in both categories. Owing to
the ambiguity in the other two categories that will require
further investigation, 39 athletes who fell in these two cat-
egories were excluded from the comparison of population
estimates. Categorisation for nutritional supplement users
was conducted in the same manner.
Population estimates for doping and nutritional supple-
ment use were obtained in two forms. Athletes were asked
in a straightforward manner to estimate the percentage of
athletes, in general, who use doping or nutritional supple-
ments. Hypothetical situations identical to the self-
reported hypothetical situations (HDS-Self) were also
used. Estimates given as percentages were used as reported
for the direct general estimates and were averaged for the
eight scenarios. Comparisons of group means were per-
formed with Mann-Whitney non-parametric statistics
using SPSS 15.0, and R statistical software was used for
Fisher's Exact Test for Count Data.
Sample
Data were collected among UK sports science students
and student athletes (n = 142) using a web-based anony-
mous questionnaire. 124 participants met the criteria of
taking part in sport at the designated competitive level.
Competitive level was defined as regular participation in
organised sports competition. Given the nature of the
present sample (sports science students and student ath-
letes), competition equates club level competition here.
The sample consisted of 46 (37.1%) female and 78
(62.9%) male athletes with mean age of 21.47 ± 5.53.
User vs. non-user groups were established using self-
reported information on doping use and intention to use
PEDs in hypothetical situations. Based on the self
reported doping use and potential use, respondents were
categorised into four groups: users with current and
potential use (n = 9), potential users with no current use
(n = 31), 'ambiguous' users with current use but denied
potential use (n = 8) and non-users (n = 76).
Results and discussion
Scale reliability coefficients for HDS scales were reassur-
ingly above the customary cut-off value (α = .886 for PED
and α = .917 for NS), suggesting good internal consist-
ency. Observed differences in the mean estimation of PED
use made by the user group exceeded the estimation made
by the non-users (35.11% vs. 15.34% for general doping
and 34.25% vs. 26.30% in hypothetical situations, respec-
tively) providing evidence in support of the FCE concept
(Figure 1). The difference, however, was only statistically
significant for the general estimation (U = 143.00, p =
.004) but not for the summarised hypothetical situations
(U = 247.00, p = .175, d = .476). The other two groups
(potential users and the ambiguous group) showed con-
siderable inconsistency, suggesting that these answers (as
well as the self-reported information on which group
membership was established) have most likely been influ-
enced by the perceived need for socially desirable
responding. Notably, the variance in estimations was con-
siderably less among the self-declared clean athletes.
Following the methods used in previous research [19,25],
the accuracy of estimates were calculated as the difference
between the estimate given by the participants (X) and the
actual population figure (P). The population figures we
used were i) the official rate of positive doping tests
reported yearly by the WADA (2%) and ii) self-reported
doping behaviour in the sample (13.7%, 95%CI = .08,
20.0). The accuracy of an estimate is the degree to which
responses reflect reality. Accuracy of the estimates for our
sample using i) self-reported information for population
prevalence and ii) official rate of positive tests showed sig-
Estimation of doping use (blue) and hypothetical doping use (green) am ng thers (disp ayed as means and 95% confi-dence intervals)Figure 1
Estimation of doping use (blue) and hypothetical 
doping use (green) among others (displayed as 
means and 95% confidence intervals).Page 5 of 8
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143.00, p = .004 and U = 143.00, p = .004, respectively).
However, the problem with this method arises from the
uncertainty regarding population prevalence. The preva-
lence rate calculated from self-reports (which itself may be
under-reported owing to the social desirability effect) sug-
gests a considerably higher prevalence rate compared to
the official yearly reports of the World Anti-Doping
Agency (13.7% vs. 2%).
Notably, even the lowest estimations given by athletes
were considerably above the average rate of positive dop-
ing tests (ca 2% of all tests according to the WADA yearly
reports [3]), which may either signal the widespread belief
that competitors are using doping (hence it is perceived as
normative behaviour) or give a closer and more realistic
estimate of doping prevalence. More importantly, the sig-
nificant overestimation by doping users suggests that if
such an indirect method is further refined and validated,
it may be successfully employed in large scale prevalence
studies as a low-cost, reliable measurement tool to capture
the prevalence of doping behaviour.
From the FET, the odds ratio is 6.025, 95%CI = 1.365,
31.186 (ln = 1.82), suggesting that doping use is more
likely among those who estimate doping use in others
beyond the sample prevalence upper 95%CI (20%).
Notably, the lower bound of the 95% CI is above 1, sug-
gesting that the difference is significant at the 95% confi-
dence level. The p value of .007 provides further
reassurance that the true OR is > 1.
Results regarding nutritional supplements suggest that
social projection is influenced by the social judgement of
the behaviour. For nutritional supplements (NS), 57 ath-
letes (46%) reported current use with a further 61 who
would consider using NS and 6 athletes rejected NS use
under any circumstances. Unlike PED, the 'ambiguous'
cell (current use with denied hypothetical use) was empty
for NS.
The comparison using estimated NS prevalence as out-
come revealed similar but less marked patterns than the
same analyses with projected PED use. Doping users' esti-
mation of NS use of others were higher than the estima-
tion made by non-users for both general estimation
(54.15 ± 30.19 vs.46.72 ± 27.34%) and hypothetical situ-
ations (74.79 ± 22.90% vs. 59.68 ± 20.40%), but the dif-
ferences were not or close not non-significant (U =
295.00, p = .500 and U = 203.50, p = .048, respectively).
The mean direct prevalence estimations (54% and 47%)
were close to the actual sample prevalence of 46%. The
estimates of hypothetical NS use by others (73% vs. 60%)
were actually below the actual self-reports of the same
behaviour (95%).
Conclusion
It is evident from the literature that categorisation
(involved vs. not involved in an act) was typically based
on self-reports, which are known to be susceptible to
response bias. Results from this pilot study, in addition to
providing important evidence for the presence of the FCE,
have flagged this problem as well. Social projection
appears to be dependent on the social judgement of the
behaviour. Therefore, it is suggested that FCE-based
assessment, coupled with using objective indicators of
behaviour (i.e. biochemical analyses) should be used in
prevalence studies on socially sensitive issues (such as
using PEDs), instead of relying on the dubious results of
self-reports.
Significance
Epidemiological and social science based research into
drugs in sport have been restricted by the absence of a via-
ble dependent variable upon which to differentiate users
from non-users. Existing self-report measures are assumed
to be significantly under-reported given that people are
unlikely to incriminate themselves by admitting use and
unable to provide a sound basis for policy makers. Thus,
alternative methods of inquiring about performance
enhancing substance (or method) use are needed. One
such alternative method makes use of results from social
psychology to develop a possible proxy that may prove
reliable, benefiting from the FCE. The measurement tool
is not envisaged to be used to gather data on projected use,
but rather, employed as an implicit self-report method. A
model will be developed to give an estimation of 'own'
use based on the projected use.
Biochemical validation of self-reported drug use can pro-
vide researchers with objective information upon which
categorisation (users vs. non-users) is made, hence it is
proposed to be used for validation of self-reports. There-
fore this project proposes an elegant integration of bio-
chemistry, social psychology and statistics to tackle the
problem of obtaining reliable estimate for the prevalence
of doping.
The measurement tool is to be used as a research tool to
gather information on prevalence of PED use but it is not
intended to be a diagnostic tool for individual assessment.
The method may also be successfully adapted to the esti-
mation of prevalence of behaviours where direct self-
reports are assumed to be distorted by socially desirable
responding. Thus this method is designed to enable col-
lecting reliable information regarding the prevalence of
PED use; and to enhance health care professionals' under-
standing of PED use. Ideally, these studies, along with
recent investigations into PED use in elite athletes [36,37]
concerning rationale vs. practice, will inform health care
professionals to target populations at risk of PED use.Page 6 of 8
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requires accurate information reflecting the true scale of
PED or drug use in various populations (i.e. athletes, non-
athletes, adolescents, adults, elderly, etc). Owing to previ-
ously demonstrated difference in strength of the FCE
[24,25,38,39], normative feedback type intervention
might be especially effective among adolescents.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
AP formulated the testable hypothesis, developed the
research design, developed the questionnaire, collected
and analysed the pilot data and drafted the manuscript.
DPN assisted in formulating the testable hypothesis,
developed the protocol for the biochemical testing and
contributed to drafting the manuscript. JM initiated the
project, contributed to developing the hypothesis and
protocol and writing the manuscript. TN developed the
web-based test site and prepared the data for statistical
analyses. SHB assisted in developing the questionnaire
and collected data for the pilot study. All authors have
read and approved the final version of the manuscript.
Additional material
Acknowledgements
AP, DN and JM have received financial assistance from the World Anti-
Doping Agency (WADA) for a research project utilising the False Consen-
sus Effect (FCE). This pilot study is the first step toward the reaching the 
project objectives.
References
1. Kayser B, Mauron A, Miah A: Current anti-doping policy: A crit-
ical appraisal.  BMC Medical Ethics 2007, 8:2.
2. Yesalis CE, Kopstein AN, Bahrke MS: Difficulties in estimating
the prevalence of drug use among athletes.  In Doping in elite
sport: The politics of drugs in the Olympic movement Edited by: Wilson
W, Derse E. Human Kinetics; 2001:43-62. 
3. WADA Annual Reports between 2002 – 2006   [http://
www.wada-ama.org/en/dynamic.ch2?pageCategory.id=453]
4. Waddington I: Changing patterns of drug use in British sport
from the 1960s.  Sport History 2005, 25:472-496.
5. Morgan WJ: Fair is fair, or is it?: A moral consideration of the
doping wars in American sport.  Sport Society 2006, 9:177-198.
6. Laure P: Epidemiologic approach of doping in sport.  J Sports
Med Phys Fitness 1997, 37(3):218-224.
7. Papadopoulos F, Skalkidis I, Parkkari J, Petridou E, "Sports Injuries"
European Union Group: Doping use among tertiary education
students in six developed countries.  Europ J Epidemiol 2006,
21:307-313.
8. Trout GJ, Kazlauskas R: Sports drug testing – an analyst's per-
spective.  Chem Soc Rev 2004, 33:1-13.
9. Lara D, Garcia SG, Ellertson C, Camlin C, Suarez J: The measure of
induced abortion levels in Mexico using random response
technique.  Soc Methods Res 2006, 35:279-301.
10. Nishimura YH, Ono-Kihara M, Mohithm JC, Ng Man Sun R, Homma
T, DiClemente RJ, Lang DL, Kihara M: Sexual behaviors and their
correlates among young people in Mauritius: a cross-sec-
tional study.  BMC Int Health Human Rights 2007, 7:8.
11. Lensvelt-Mulders GJLM, Hox JJ, Heijden PGM van der, Maas CJM:
Meta-analysis of randomised response research.  Soc Methods
Res 2005, 33:319-348.
12. Simon P, Striegel H, Aust F, Dietz K, Ulrich R: Doping in fitness
sports: estimated number of underreported cases and indi-
vidual probability of doping.  Addition 2006, 101:1640-1644.
13. Allport FH: Social Psychology Cambridge, MA: Riverside Press; 1924. 
14. Agostinelli G, Seal DW: Social comparison of one's own with
others attitudes towards causal and responsible sex.  J Appl Soc
Psychol 1988, 28:845-860.
15. Buunk BP, Kluwer ES, Schuurman MK, Siero FW: The division of
labor among egalitarian and traditional women: differences
in discontent, social comparison and false consensus.  J Appl
Soc Psychol 2000, 30:759-779.
16. Buunk BP, Eijden RJJ van den, Siero FW: The double-edged sword
of providing information about the prevalence of safe sex.  J
Appl Soc Psychol 2002, 32:684-699.
17. Monin B, Norton MI: Perceptions of a fluid consensus: unique-
ness bias, false consensus, false polarization, and pluralistic
ignorance in a water conservation crisis.  Personal Soc Psychol Bull
2003, 29:559-567.
18. Suls J, Wan CK, Sanders GS: False consensus and false unique-
ness in estimating the prevalence of health-protective
behaviours.  J Appl Soc Psychol 1988, 18:66-79.
19. Wolfson S: Students' estimates of the prevalence of drug use:
evidence for a false consensus effect.  Psychol Addict Behav 2000,
14:295-298.
20. Holmes DS: Dimensions of projection.  Psychol Bullet 1968,
69:248-268.
21. Ross L, Greene D, House P: The false consensus effect: An ego-
centric bias in social perception and attribution processes.  J
Exp Socl Psychol 1977, 13:279-301.
22. Krueger J, Clement RW: The truly false consensus effect: an ine-
radicable and egocentric bias in social perception.  J Pers Soc
Psychol 1994, 67:596-610. [Erratum in: J Pers Soc Psychol 1995, 68:579].
23. Gershoff AD, Mukherjee A, Mukhopadhyay A: What's not to like?
Preference asymmetry in the false consensus effect.  J Con-
sumer Res 2007, 31(1):119-125.
24. Juvonen J, Martino SC, Ellickson PL, Longshore D: But others do
it!": Do misperception of schoolmate alcohol and marijuana
use predict subsequent drug use among young adolescents.
J Appl Soc Psychol 2007, 37:740-758.
25. Lai MK, Ho SY, Lam TH: Perceived peer smoking prevalence
and its association with smoking behaviours and intentions in
Hong Kong Chinese adolescents.  Addiction 2007, 99:1195-1205.
26. McCabe SE: Misperceptions of non-medical prescription drug
use: a web-survey of college students.  Addict Behav 2008,
33:713-724.
27. Pearson B, Hansen B: Survey of U.S. Olympians.  USA Today.
February 5, 1992, 10C.
28. Alaranta A, Alaranta H, Holmila J, Palmu P, Pietila K, Helenius I: Self-
reported attitudes of elite athletes towards doping: differ-
ences between type of sport.  Int J Sport Med 2006, 27:842-846.
29. Backhouse S, McKenna J, Robinson S, Atkin A: Attitudes, Behav-
iours, Knowledge and Education – Drugs in Sport: Past,
Present and Future 2007.   [http://www.wada-ama.org].
Additional File 1
Direct doping estimate of others, Self reported doping behaviour, HDS 
and HDS-Self. The file shows the questions used for self-reporting and 
estimating doping behaviour directly and in hypothetical situations.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1745-
6673-3-19-S1.doc]
Additional file 2
Definition of nutritional supplements and doping. The file provides defi-
nitions for drug categories used in the questionnaire.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1745-
6673-3-19-S2.doc]Page 7 of 8
(page number not for citation purposes)
Journal of Occupational Medicine and Toxicology 2008, 3:19 http://www.occup-med.com/content/3/1/19Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
30. Ashraf W, Jaffar M, Anwer K, Ehsan U: Age- and sex-based com-
parative distribution of selected metals in the scalp hair of an
urban population from two cities in Pakistan.  Environ Pollut
1995, 87:61-64.
31. Pragst F, Balikova MA: State of the art in hair analysis for detec-
tion of drug and alcohol abuse.  Clin Chim Acta 2006, 370:17-49.
32. Forte G, Alimonti A, Violante N, Di Gregorio M, Senofonte O,
Petrucci F, Giuseppe Sancesario G, Bocca B: Calcium, copper,
iron, magnesium, silicon and zinc content of hair in Parkin-
son's disease.  J Trace Elem Exp Med 2005, 19:195-201.
33. Rao KS, Balaji T, Rao TP, Babu Y, Naidu GRK: Determination of
iron, cobalt, nickel, manganese, zinc, copper, cadmium and
lead in human hair by inductively coupled plasma atomic
emission spectrometry.  Spectrochim Acta Part 2002,
57:1333-1338.
34. Pujol ML, Cirimele V, Tritsch P, Villain M, Kintz P: Evaluation of the
IDS One-StepTM ELISA kits for the detection of illicit drugs
in hair.  Forensic Sci Int 2007, 170:189-192.
35. Dumestre-Toulet V, Cirimele V, Ludes B, Gromb S, Kintz P: Hair
analysis of seven bodybuilders for anabolic steroids, ephe-
drine and clenbuterol.  J Forensic Sci 2002, 47:211-214.
36. Petroczi A, Naughton DP, Mazanov J, Holloway A, Bingham J: Per-
formance enhancement with supplements: incongruence
between rationale and practice.  J Int Soc Sports Nutr 2007, 4:19.
37. Petroczi A, Naughton DP, Mazanov J, Holloway A, Bingham J: Lim-
ited agreement exists between rationale and practice in ath-
letes' supplement use for maintenance of health: a
retrospective study.  Nutr J 2007, 6:34.
38. Cunningham JA, Selby PL: Implications of the normative fallacy
in young adult smokers aged 19–24 Years.  Am J Pub Health
2007, 97:1399-1400.
39. Petroczi A, Aidman EV: Psychological drivers in doping: the life-
cycle model of performance enhancement.  Subst Abuse Treat
Prev Policy 2008, 3:7.Page 8 of 8
(page number not for citation purposes)
